MRES Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Institute of Biomedical Research's net margin of -49.65%. Institute of Biomedical Research's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Institute of Biomedical Research has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 464.39%. Given that NovaBay Pharmaceuticals has higher upside potential than Institute of Biomedical Research, analysts believe NovaBay Pharmaceuticals is more attractive than Institute of Biomedical Research.

Institute of Biomedical Research has a beta of 2.581, which suggesting that the stock is 158.057% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Institute of Biomedical Research has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Institute of Biomedical Research pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Institute of Biomedical Research quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Institute of Biomedical Research's net income of -- is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Institute of Biomedical Research's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Institute of Biomedical Research is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Institute of Biomedical Research's net margin of --. Institute of Biomedical Research's return on equity of -- beat Oragenics's return on equity of --.

Institute of Biomedical Research has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 23900%. Given that Oragenics has higher upside potential than Institute of Biomedical Research, analysts believe Oragenics is more attractive than Institute of Biomedical Research.

Institute of Biomedical Research has a beta of 2.581, which suggesting that the stock is 158.057% more volatile than S&P 500. In comparison Oragenics has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.712%.

Institute of Biomedical Research has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Institute of Biomedical Research pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Institute of Biomedical Research quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Institute of Biomedical Research's net income of -- is lower than Oragenics's net income of -$2.5M. Notably, Institute of Biomedical Research's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Institute of Biomedical Research is -- versus 1.48x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Institute of Biomedical Research's net margin of -2357.27%. Institute of Biomedical Research's return on equity of -- beat Palatin Technologies's return on equity of --.

Institute of Biomedical Research has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1304.96%. Given that Palatin Technologies has higher upside potential than Institute of Biomedical Research, analysts believe Palatin Technologies is more attractive than Institute of Biomedical Research.

Institute of Biomedical Research has a beta of 2.581, which suggesting that the stock is 158.057% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Institute of Biomedical Research has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Institute of Biomedical Research pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Institute of Biomedical Research quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Institute of Biomedical Research's net income of -- is lower than Palatin Technologies's net income of -$7.8M. Notably, Institute of Biomedical Research's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Institute of Biomedical Research is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Institute of Biomedical Research's net margin of --. Institute of Biomedical Research's return on equity of -- beat Theriva Biologics's return on equity of --.

Institute of Biomedical Research has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 5486.42%. Given that Theriva Biologics has higher upside potential than Institute of Biomedical Research, analysts believe Theriva Biologics is more attractive than Institute of Biomedical Research.

Institute of Biomedical Research has a beta of 2.581, which suggesting that the stock is 158.057% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

Institute of Biomedical Research has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Institute of Biomedical Research pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Institute of Biomedical Research quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Institute of Biomedical Research's net income of -- is lower than Theriva Biologics's net income of -$7.7M. Notably, Institute of Biomedical Research's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Institute of Biomedical Research is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.